https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-302014-01-01 00:00:002021-11-15 16:55:45Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Immunotherapy 2014;6(3):349-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Immunotherapy 2014;6(3):349-602014-01-01 00:00:002019-02-15 08:50:00Dendritic cell-based vaccines: clinical applications in breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-13 / Front Immunol 2013 Dec;4:454
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-13 / Front Immunol 2013 Dec;4:4542013-12-13 00:00:002019-02-15 08:39:46Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-03 / Front Immunol 2013 Dec;4:417
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-03 / Front Immunol 2013 Dec;4:4172013-12-03 00:00:002019-02-15 08:36:00Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-12-01 / Anticancer Res 2013 Dec;33(12):5495-5002013-12-01 00:00:002024-03-18 10:53:49Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-18 / Front Immunol 2013 Nov;4:382
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-18 / Front Immunol 2013 Nov;4:3822013-11-18 00:00:002020-02-05 10:32:56Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-4062013-11-12 00:00:002021-11-15 13:32:44Myeloid-derived suppressor cells in glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e270592013-11-06 00:00:002021-11-15 13:33:23Dendritic cell-based immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-05 / Autoimmunity 2014 Feb;47(1):46-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-05 / Autoimmunity 2014 Feb;47(1):46-562013-11-05 00:00:002019-02-15 08:45:31Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-01 / Cancer J 2013 Nov-Dec;19(6):511-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-01 / Cancer J 2013 Nov-Dec;19(6):511-62013-11-01 00:00:002013-11-01 00:00:00Dendritic cells, inflammation, and breast cancer
